Advertisement

Cell Harvest and Purification Technology — State of the Art and Future Development

Conference paper
Part of the Developments in Hematology and Immunology book series (DIHI, volume 38)

Abstract

Different WBC populations in human blood can be collected for cancer therapy. Hematopoietic stem/progenitor cells (HSPC), originally harvested from bone marrow, are now increasingly collected from blood for autologous and allogeneic transplantations. Umbilical cord blood, discarded until recently, has become a source of HSPC [1–4]. Recently, HSPC have been shown to have the potential to develop into cells of other organ systems [5–21]. In the laboratory, it is possible to grow cells of neural, hepatic cells, and cardiac origins from the bone marrow [20,21]. Clinical protocols are being developed to test the hypothesis of the plasticity of the HSPC.

Keywords

Peripheral Blood Stem Cell Autologous Bone Marrow Peripheral Blood Progenitor Cell Cell Separation System Counterflow Centrifugal Elutriation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Harris DT, Schumacher MJ, Rychlik S, et al. Collection, separation and cryopreservation of umbilical cord blood for use in transplantation. Bone Marrow Transplant 1994; 13:135–43.PubMedGoogle Scholar
  2. 2.
    Lazzari L, Corsini C, Curioni C, et al. The Milan Cord Blood Bank and the Italian Cord Blood Network. J Hematother 1996;5:117–22.PubMedCrossRefGoogle Scholar
  3. 3.
    McCullough J, Clay M, Wagner JE. Cord blood stem cells. In: Law P, editor. Hematopoietic stem cell therapy. 1st ed. New York: Churchill Livingstone; 2000. p. 287–97.Google Scholar
  4. 4.
    Rubinstein P, Dobrila L, Rosenfield RE, et al. Processing and cryopreserva-tion of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci U S A 1995;92:10119–22.PubMedCrossRefGoogle Scholar
  5. 5.
    Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41–49.PubMedCrossRefGoogle Scholar
  6. 6.
    Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002;109:337–46.PubMedGoogle Scholar
  7. 7.
    Schwartz RE, Reyes M, Koodie L, et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 2002;109:1291–302.PubMedGoogle Scholar
  8. 8.
    Zhao LR, Duan WM, Reyes M, Keene CD, Verfaillie CM, Low WC. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol 2002;174:11–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Abkowitz JL. Can human hematopoietic stem cells become skin, gut, or liver cells? N Engl J Med 2002;346:770–72.PubMedCrossRefGoogle Scholar
  10. 10.
    Ferrari G, Cusella-De Angelis G, Coletta M, et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998;279:1528–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Jackson KA, Majka SM, Wang H, et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001; 107:1395–402.PubMedCrossRefGoogle Scholar
  12. 12.
    Korbling M, Katz RL, Khanna A, et al. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med 2002;346:738–46.PubMedCrossRefGoogle Scholar
  13. 13.
    Kotton DN, Ma BY, Cardoso WV, et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 2001;128:5181–88.PubMedGoogle Scholar
  14. 14.
    Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lineage en-graftment by a single bone marrow-derived stem cell. Cell 2001;105:369–77.PubMedCrossRefGoogle Scholar
  15. 15.
    McKinney-Freeman SL, Jackson KA, Camargo FD, Ferrari G, Mavilio F, Goodell MA. Muscle-derived hematopoietic stem cells are hematopoietic in origin. Proc Natl Acad Sci U S A 2002;99:1341–46.PubMedCrossRefGoogle Scholar
  16. 16.
    Orlic D, Kajsrura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 2001;98:10344–49.PubMedCrossRefGoogle Scholar
  17. 17.
    Petersen BE, Bowen WC, Patrene KD, et al. Bone marrow as a potential source of hepatic oval cells. Science 1999;284:1168–70.PubMedCrossRefGoogle Scholar
  18. 18.
    Priller J, Persons DA, Klett FF, Kempermann G, Kreutzberg GW, Dirnagl U. Neogenesis of cerebellar Purkinje neurons from gene-marked bone marrow cells in vivo. J Cell Biol 2001;155:733–38.PubMedCrossRefGoogle Scholar
  19. 19.
    Theise ND, Nimmakayalu M, Gardner R, et al. Liver from bone marrow in humans. Hepatology 2000;32:11–16.PubMedCrossRefGoogle Scholar
  20. 20.
    Barry F, Boynton RE, Liu B, Murphy JM. Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components. Exp Cell Res 2001;268:189–200.PubMedCrossRefGoogle Scholar
  21. 21.
    Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002;105:93–98.PubMedCrossRefGoogle Scholar
  22. 22.
    Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041–50.PubMedGoogle Scholar
  23. 23.
    Meehan KR, Verma UN, Mazumder A. Immunomodulation after transplantation. In: Law P, editor. Hematopoietic stem cell therapy. New York: Churchill Livingstone; 2000. pp. 345–53.Google Scholar
  24. 24.
    Small E, Fratesi R, Reese D, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894–903.PubMedGoogle Scholar
  25. 25.
    Murphy GP, Tjoa BA, Simmons SJ, et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999;39:54–59.PubMedCrossRefGoogle Scholar
  26. 26.
    Tjoa BA, Erickson SJ, Bowes VA, et al. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 1997;32:272–78.PubMedCrossRefGoogle Scholar
  27. 27.
    Tjoa BA, Simmons SJ, Bowes VA, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998;36:39–44.PubMedCrossRefGoogle Scholar
  28. 28.
    Nguyen XD, Eichler H, Sucker A, Hofmann U, Schadendorf D, Kluter H. Collection of autologous monocytes for dendritic cell vaccination therapy in metastatic melanoma patients. PG. Transfusion 2002;42: 428–32.PubMedCrossRefGoogle Scholar
  29. 29.
    Falkenburg JH, Faber LM, van den Elshout M, , et al. Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation. J Immunother 1993;14:305–09.CrossRefGoogle Scholar
  30. 30.
    Marijt WA, Kernan NA, Diaz-Barrientos T, et al. Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation. Bone Marrow Transplant 1995;16:125–32.PubMedGoogle Scholar
  31. 31.
    Smit WM, Rijnbeek M, van Bergen CA, Willemze R, Falkenburg JH. Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay. Bone Marrow Transplant 1998;21:553–60.PubMedCrossRefGoogle Scholar
  32. 32.
    Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999;94:1201–08.PubMedGoogle Scholar
  33. 33.
    Gillespie G, Mutis T, Schrama E, et al. HLA class I-minor histocompatibility antigen tetramers select cytotoxic T cells with high avidity to the natural ligand. Hematol J 2000;1:403–10.PubMedCrossRefGoogle Scholar
  34. 34.
    Marijt WA, Falkenburg JH. Specific T cell therapy in leukemia. J Hematother Stem Cell Res 2001;10:493–500.PubMedCrossRefGoogle Scholar
  35. 35.
    Riddell SR, Greenberg PD, Overell RW, et al. Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology. Hum Gene Ther 1992;3:319–38.PubMedCrossRefGoogle Scholar
  36. 36.
    Riddell SR, Warren EH, Gavin MA, et al. Immunotherapy of human viral and malignant diseases with genetically modified T-cell clones. Cancer J 2000;6 Suppl 3:S250–58.PubMedCrossRefGoogle Scholar
  37. 37.
    Riddell SR, Murata M, Bryant S, Warren EH. T-cell therapy of leukemia. Cancer Control 2002;9:114–22.PubMedGoogle Scholar
  38. 38.
    Peshwa M, Page L, Qian L, Yang D, van Schooten W. Generation and ex vivo expansion of HTLV-1 specific CD8+ cytotoxic T-lymphocytes for adoptive immunotherapy. Biotechnology and Bioengineering 1996;50:529–40.PubMedCrossRefGoogle Scholar
  39. 39.
    Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defmed human minor histocompatibility antigens with a restricted tissue distribution. Blood 1998;91:2197–207.PubMedGoogle Scholar
  40. 40.
    Yee C, Gilbert MJ, Riddell SR, et al. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol 1996;157:4079–86.PubMedGoogle Scholar
  41. 41.
    Yee C, Riddell SR, Greenberg PD. Prospects for adoptive T cell therapy. Curr Opin Immunol 1997;9:702–08.PubMedCrossRefGoogle Scholar
  42. 42.
    Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038–44.PubMedCrossRefGoogle Scholar
  43. 43.
    Dettke D, Berger R, Jurko S, Mitterbauer G, Schwarzmeier J, Hocker P. Selection of autologous CD4+ T cells for adoptive T-cell substitution in patients with CD23+ B cell chronic lymphocytic leukemia. Cytotherapy 2002; 4:119–25.PubMedCrossRefGoogle Scholar
  44. 44.
    Hitzler WE, Wolf S, Runkel S, Kunz-Kostomanolakis M. Comparison of intermittent- and continuous-flow cell separators for the collection of autologous peripheral blood progenitor cells in patients with hematologic malignancies. PG -. Transfusion 2001;41:1562–66.PubMedCrossRefGoogle Scholar
  45. 45.
    McMannis J, Thomas M, Maandani F, et al. Comparison of two clinical systems for CD34+ cell isolation. Cytotherapy 2000;2:326.Google Scholar
  46. 46.
    Ravagnani F, Siena S, De Reys S, et al. Improved collection of mobilized CD34+ hematopoietic progenitor cells by a novel automated leukapheresis system. Transfusion 1999;39:48–55.PubMedCrossRefGoogle Scholar
  47. 47.
    Snyder EL, Baril L, Cooper DL, et al. In vitro collection and posttransfusion engraftment characteristics of MNCs obtained by using a new separator for autologous PBPC transplantation. PG. Transfusion 2000;40: 961–67.PubMedCrossRefGoogle Scholar
  48. 48.
    Snyder EL, O’Donnell L, Dengler TJ, et al. Ex vivo evaluation of PBMNCs collected with a new cell separator. Transfusion 2001;41:940–49.PubMedCrossRefGoogle Scholar
  49. 49.
    Stainer CJ, Miilin G, Anderson S, Davy B, McQuaker IG, Russell NH. A comparison of two different systems for CD34+ selection of autologous or allogeneic PBSC collections. J Hematother 1998;7:375–83.PubMedCrossRefGoogle Scholar
  50. 50.
    Hillyer CD. Large volume leukapheresis to maximize peripheral blood stem cell collection. I Hematother 1993;2:529–32.CrossRefGoogle Scholar
  51. 51.
    Lane TA, Law P, Maruyama M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995;85: 275–82.PubMedGoogle Scholar
  52. 52.
    Smolowicz AG, Villman K, Tidefelt U. Large-volume apheresis for the harvest of peripheral blood progenitor cells for autologous transplantation. Transfusion 1997;37:188–92.PubMedCrossRefGoogle Scholar
  53. 53.
    Meisenberg B, Brehm T, Schmeckel A, Miller W, McMillan R. A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than granulocyte-colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells. Transfusion 1998;38: 209–15.PubMedCrossRefGoogle Scholar
  54. 54.
    Lane TA. Peripheral blood progenitor cell mobilization and collection. In: Law P, editor. Hematopoietic stem cell therapy. 1st ed. New York: Churchill Livingstone; 2000. pp. 269–86.Google Scholar
  55. 55.
    Ho AD, Gluck S, Germond C, et al. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer. Leukemia 1993;7:1738–46.PubMedGoogle Scholar
  56. 56.
    Sato N, Sawada K, Takahashi TA, et al. A time course study for optimal harvest of peripheral blood progenitor cells by granulocyte colony-stimulating factor in healthy volunteers. Exp Hematol 1994;22:973–78.PubMedGoogle Scholar
  57. 57.
    Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994;83: 3068–76.PubMedGoogle Scholar
  58. 58.
    Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993;341:85–86.PubMedCrossRefGoogle Scholar
  59. 59.
    Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991;325:1525–33.PubMedCrossRefGoogle Scholar
  60. 60.
    Tyer CL, Vredenburgh JJ, Heimer M, Peters WP, Bast RC, Jr. Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique. Clin Cancer Res 1996;2:81–86.PubMedGoogle Scholar
  61. 61.
    Weaver CH, Moss T, Schwartzberg LS, et al. High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells. Bone Marrow Transplant 1998;21:1117–124.PubMedCrossRefGoogle Scholar
  62. 62.
    Kruger W, Gruber M, Hennings S, et al. Purging and haemopoietic progenitor cell selection by CD34+ cell separation. Bone Marrow Transplant 1998; 21:665–71.PubMedCrossRefGoogle Scholar
  63. 63.
    Moss TJ, Sanders DG, Lasky LC, Bostrom B. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990; 76:1879–83.PubMedGoogle Scholar
  64. 64.
    Gee A. Purging of peripheral blood stem cell grafts. Stem Cells 1995;13 Suppl 3:52–62.PubMedCrossRefGoogle Scholar
  65. 65.
    Kernan NA, Bordignon C, Heller G, et al. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. Blood 1989;74: 2227–36.PubMedGoogle Scholar
  66. 66.
    Law P. Graft processing, storage, and infusion. In: Law P, editor. Hematopoietic stem cell therapy. 1st ed. New York: Churchill Livingstone; 2000. pp. 312–21.Google Scholar
  67. 67.
    Donnenberg AD. T-cell depletion and allograft engineering. In: Law P, editor. Hematopoietic stem cell therapy. 1st ed. New York: Churchill Livingstone; 2000. pp. 335–44.Google Scholar
  68. 68.
    Butrurini A, Gale RP. T cell depletion in bone marrow transplantation for leukemia: current results and future directions. Bone Marrow Transplant 1988;3:185–92.Google Scholar
  69. 69.
    Dunbar C, Kohn D. Retroviral mediated transfer of the cDNA for human glucocerebrosidase into hematopoietic stem cells of patients with Gaucher disease. A phase I study. Hum Gene Ther 1996;7:231–53.PubMedCrossRefGoogle Scholar
  70. 70.
    Montagna D, Maccario R, Locatelli F, et al. Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood 2001;98:3359–66PubMedCrossRefGoogle Scholar
  71. 71.
    Przepiorka D, Van Vlasselaer P, Huynh L, et al. Rapid debulking and CD34 enrichment of filgrastim-mobilized peripheral blood stem cells by semiautomated density gradient centrifugation in a closed system. J Hematother 1996;5:497–502.PubMedCrossRefGoogle Scholar
  72. 72.
    Law P, Dooley DC, Alsop P, Smith DM, Landmark JD, Meryman HT. Density gradient isolation of peripheral blood mononuclear cells using a blood cell processor. Transfusion 1988;28:145–50.PubMedCrossRefGoogle Scholar
  73. 73.
    Rowley SD, Davis JM, Piantadosi S, Jones RJ, Yeager AM, Santos GW. Density-gradient separation of autologous bone marrow grafts before ex vivo purging with 4-hydroperoxycyclophosphamide. Bone Marrow Transplant 1990;6:321–27.PubMedGoogle Scholar
  74. 74.
    Gilmore MJ, Prentice HG, Blacklock HA, Janossy G, Hoffbrand AV. A technique for rapid isolation of bone marrow mononuclear cells using Ficoll-Metrizoate and the IBM 2991 blood cell processor. Br J Haematol 1982; 50:619–26.PubMedCrossRefGoogle Scholar
  75. 75.
    Jin NR, Hill R, Segal G, et al. Preparation of red-blood-cell-depleted marrow for ABO-incompatible marrow transplantation by density-gradient separation using the IBM 2991 blood cell processor. Exp Hematol 1987;15:93–98.PubMedGoogle Scholar
  76. 76.
    Neudorf SM, Rybka W, Ball E, et al. The use of counterflow centrifugal elutriation for the depletion of T cells from unrelated donor bone marrow. J Hematother 1997;6:351–59.PubMedCrossRefGoogle Scholar
  77. 77.
    Wagner JE, Donnenberg AD, Noga SJ et al. Lymphocyte depletion of donor bone marrow by counterflow centrifugal elutriation: results of a phase I clinical trial. Blood 1988;72:1168–76.PubMedGoogle Scholar
  78. 78.
    Wong EC, Lee SM, Hines K, et al. Development of a closed-system process for clinical-scale generation of DCs: evaluation of two monocyte-enrichment methods and two culture containers. PG Cytotherapy 2002;4:65–76.CrossRefGoogle Scholar
  79. 79.
    Dooley D. Glycerol permeation of the human granulocyte. Exp Hematol 1982;10:411–20.Google Scholar
  80. 80.
    Shpall EJ, Jones RB, Bearman SI, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994;12:28–36.PubMedGoogle Scholar
  81. 81.
    Shpall EJ, Jones RB, Bearman SI, et al. Transplantation of CD34+ hematopoietic progenitor cells. J Hematother 1994;3:145–47.PubMedCrossRefGoogle Scholar
  82. 82.
    Shpall EJ, LeMaistre CF, Holland K, et al. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood 1997; 90:4313–20.PubMedGoogle Scholar
  83. 83.
    Tseng-Law J, Szalay P, Guillermo R, et al. Identification of a peptide directed against the anti-CD34 antibody, 9C5, by phage display and its use in hematopoietic stem cell selection. Exp Hematol 1999;27:936–45.PubMedCrossRefGoogle Scholar
  84. 84.
    Chabannon C, Cornetta K, Lotz JP, et al. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study. Br J Cancer 1998; 78:913–21.PubMedCrossRefGoogle Scholar
  85. 85.
    Houde H, Zhu H, Schmittling R, Cook D, Monroy R. A simulated use controlled study of 22 normal volunteers using the BCell-HDM cell separation system demonstrates highly efficient depletion of CD20+ B cells and high recovery of CD34+ and CD3+ cells. Blood 2000;96:187a.Google Scholar
  86. 86.
    Chang Q, Houde H, Schmittling R, Zhu H, Cook D, Monroy R. PBSC evaluation of two and three depletion cycles on CD8+ T cell depletion and CD34+ cell recovery from PBSC products using the Eligix T Cell-HDM cell separation system. Cytotherapy 2001;6:525.Google Scholar
  87. 87.
    Prince H, Bashford J, Wall D, et al. Isolex-300i CD34-selected cells to support multiple cycles of high dose therapy. Cytotherapy 2002;4:137–45.PubMedCrossRefGoogle Scholar
  88. 88.
    Prince H, Wall D, Rischin D, et al. CliniMACS CD34-selected cells to support multiple cycles of high dose therapy. Cytotherapy 2002;4:147–55.PubMedCrossRefGoogle Scholar
  89. 89.
    McNiece I, Briddell R, Stoney G, et al. Large-scale isolation of CD34+ cells using the Amgen cell selection device results in high levels of purity and recovery. J Hematother 1997;6:5–11.PubMedCrossRefGoogle Scholar
  90. 90.
    de Wynter EA, Coutinho LH, Pei X, et al. Comparison of purity and enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral blood (primed for apheresis) using five separation systems. Stem Cells 1995;13:524–32.PubMedCrossRefGoogle Scholar
  91. 91.
    Bjorkstrand B, Sundman-Engberg B, Christensson B, Kumlien G. A controlled comparison of two different clinical grade devices for CD34+ cell selection of autologous blood stem cell grafts. J Hematother 1999;8:75–80.PubMedCrossRefGoogle Scholar
  92. 92.
    Civin CI, Trischmann T, Kadan NS, et al. Highly purified CD34-positive cells reconstitute hematopoiesis. J Clin Oncol 1996;14:2224–33.PubMedGoogle Scholar
  93. 93.
    Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992;1:329–41.PubMedCrossRefGoogle Scholar
  94. 94.
    Suen Y, Lee SM, Aono F, et al. Comparison of monocyte enrichment by immuno-magnetic depletion or adherence for the clinical-scale generation of DC. Cytotherapy 2001;3: 365–75.PubMedCrossRefGoogle Scholar
  95. 95.
    Smith TJ, Hillner BE, Yanovich SA. Economics. In: Law P, editor. Hematopoietic stem cell therapy. 1st ed. New York: Churchill Livingstone; 2000. pp. 712–19.Google Scholar
  96. 96.
    Simpson JK, Burgunder MR. Coordination and data collection. In: Law P, editor. Hematopoietic stem cell therapy. 1st ed. New York: Churchill Livingstone; 2000. pp. 688–96.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • P. Law
    • 1
  1. 1.Dendreon Corporation, Cell Process DevelopmentSeattleUSA

Personalised recommendations